These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 3038399

  • 1. Monocrotaline-induced cardiopulmonary injury in rats: modification by thiol and nonthiol ACE inhibitors.
    Molteni A, Ward W, Ts'ao C, Solliday N.
    Clin Exp Hypertens A; 1987; 9(2-3):381-5. PubMed ID: 3038399
    [No Abstract] [Full Text] [Related]

  • 2. Monocrotaline-induced cardiopulmonary injury in rats: modification by the nonthiol ACE inhibitors CGS13945 and CGS16617.
    Molteni A, Ward WF, Ts'ao C, Solliday NH.
    Arch Int Pharmacodyn Ther; 1988; 291():21-40. PubMed ID: 3129998
    [Abstract] [Full Text] [Related]

  • 3. Monocrotaline-induced cardiopulmonary damage in rats: amelioration by the angiotensin-converting enzyme inhibitor CL242817.
    Molteni A, Ward WF, Ts'ao CH, Solliday NH.
    Proc Soc Exp Biol Med; 1986 Sep; 182(4):483-93. PubMed ID: 3016747
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin converting enzyme activity and evolution of pulmonary vascular disease in rats with monocrotaline pulmonary hypertension.
    Kay JM, Keane PM, Suyama KL, Gauthier D.
    Thorax; 1982 Feb; 37(2):88-96. PubMed ID: 6281933
    [Abstract] [Full Text] [Related]

  • 5. Monocrotaline-induced cardiopulmonary injury in rats. Modification by the neutrophil elastase inhibitor SC39026.
    Molteni A, Ward WF, Ts'ao CH, Hinz JM.
    Biochem Pharmacol; 1989 Aug 01; 38(15):2411-9. PubMed ID: 2547380
    [Abstract] [Full Text] [Related]

  • 6. Lung angiotensin converting enzyme activity in monocrotaline pulmonary hypertension.
    Keane PM, Kay JM.
    Thorax; 1984 Feb 01; 39(2):159-60. PubMed ID: 6322375
    [No Abstract] [Full Text] [Related]

  • 7. Attenuation of the toxicity of a pyrrolizidine alkaloid (monocrotaline) by metabolic inhibition.
    Eisenstein D, Azari J, Huxtable R.
    Proc West Pharmacol Soc; 1979 Feb 01; 22():193-8. PubMed ID: 160042
    [No Abstract] [Full Text] [Related]

  • 8. Monocrotaline-induced pulmonary fibrosis in rats: amelioration by captopril and penicillamine.
    Molteni A, Ward WF, Ts'ao CH, Solliday NH, Dunne M.
    Proc Soc Exp Biol Med; 1985 Oct 01; 180(1):112-20. PubMed ID: 2994075
    [Abstract] [Full Text] [Related]

  • 9. Changes in angiotensin-converting enzyme activity in lungs damaged by the pyrrolizidine alkaloid monocrotaline.
    Lafranconi WM, Huxtable RJ.
    Thorax; 1983 Apr 01; 38(4):307-9. PubMed ID: 6306859
    [Abstract] [Full Text] [Related]

  • 10. Monocrotaline pneumotoxicity in mice.
    Molteni A, Ward WF, Ts'ao CH, Solliday NH.
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1989 Apr 01; 57(3):149-55. PubMed ID: 2570481
    [Abstract] [Full Text] [Related]

  • 11. Correlative morphological and biochemical studies on monocrotaline-induced pulmonary alterations in rats.
    Hayashi Y, Kokubo T, Takahashi M, Furukawa F, Otsuka H, Hashimoto K.
    Toxicol Lett; 1984 Apr 01; 21(1):65-71. PubMed ID: 6326350
    [Abstract] [Full Text] [Related]

  • 12. Development of morphologic, hemodynamic, and biochemical changes in lungs of rats given monocrotaline pyrrole.
    Reindel JF, Ganey PE, Wagner JG, Slocombe RF, Roth RA.
    Toxicol Appl Pharmacol; 1990 Nov 01; 106(2):179-200. PubMed ID: 2256110
    [Abstract] [Full Text] [Related]

  • 13. An evaluation of procoagulant activity in the peripheral blood of rats treated with monocrotaline pyrrole.
    Schultze AE, Wagner JG, Roth RA.
    Toxicol Appl Pharmacol; 1991 Jul 01; 109(3):421-31. PubMed ID: 1830177
    [Abstract] [Full Text] [Related]

  • 14. Monocrotaline-induced pulmonary endothelial dysfunction in rats.
    Molteni A, Ward WF, Ts'ao CH, Port CD, Solliday NH.
    Proc Soc Exp Biol Med; 1984 May 01; 176(1):88-94. PubMed ID: 6324229
    [Abstract] [Full Text] [Related]

  • 15. Magnesium aspartate hydrochloride attenuates monocrotaline-induced pulmonary artery hypertension in rats.
    Mathew R, Gloster ES, Altura BT, Altura BM.
    Clin Sci (Lond); 1988 Dec 01; 75(6):661-7. PubMed ID: 2974771
    [Abstract] [Full Text] [Related]

  • 16. Monokine-induced lung injury in rats: similarities to monocrotaline-induced pneumotoxicity.
    Gillespie MN, Olson JW, Hennig B, Cohen DA, McClain CJ, Goldblum SE.
    Toxicol Appl Pharmacol; 1989 Mar 15; 98(1):134-43. PubMed ID: 2494779
    [Abstract] [Full Text] [Related]

  • 17. Alteration of monocrotaline pyrrole-induced cardiopulmonary effects in rats by hydrallazine, dexamethasone or sulphinpyrazone.
    Hilliker KS, Roth RA.
    Br J Pharmacol; 1984 Jun 15; 82(2):375-80. PubMed ID: 6234044
    [Abstract] [Full Text] [Related]

  • 18. Fulvine and the pulmonary circulation.
    Kay JM, Heath D, Smith P, Bras G, Summerell J.
    Thorax; 1971 May 15; 26(3):249-61. PubMed ID: 4253539
    [Abstract] [Full Text] [Related]

  • 19. Pulmonary vasculature in monocrotaline-induced hypertensive rats on magnesium therapy.
    Mathew R, Gloster ES, Altura BT, Altura BM.
    Microcirc Endothelium Lymphatics; 1990 May 15; 6(4-5):267-83. PubMed ID: 2149161
    [Abstract] [Full Text] [Related]

  • 20. Monocrotaline pyrrole-induced cardiopulmonary toxicity is not altered by metergoline or ketanserin.
    Ganey PE, Sprugel KH, Hadley KB, Roth RA.
    J Pharmacol Exp Ther; 1986 Apr 15; 237(1):226-31. PubMed ID: 2937908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.